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EDITORIAL
Using lithium
Lithium was first used as a mood stabiliser in 19491 and has
since been a very popular psychiatric drug. Being a simple
chemical it is not a profitable drug. Moreover, its use is not
without adverse/side-effects. Both anticonvulsants and
atypical antipsychotics (including lithium) are being used
to treat a significant percentage of patients suffering from
bipolar mood disorders. A recent survey in the United States
found that the use of lithium remained relatively stable
while that of anticonvulsants nearly doubled from 1994 to
2003.2 Occasionally lithium is also used to augment other
antidepressant drugs. The mechanism of action for this
simple ion’s mood stabilising or antidepressant action is
unknown, despite many years of research.
Lithium has been used in thousands of psychiatric
patients over the years. Available in different preparations
and formats such as extended release forms, it is a
monovalent cation, which is minimally protein bound and
excreted by the kidneys. High concentrations are toxic, while
its mood stabilising effect only occurs within a certain
range of concentrations. Thus, it is a drug with a narrow
therapeutic range (NTR) and lithium level monitoring is
considered important to ensure an adequate response and
avoid toxicity. Serum lithium levels are generally adjusted
to between 0.5 mmol/L and 1.2 mmol/L for maximum
benefits. Levels above 1.5 mmol/L are generally associated
with some toxic effects. Adverse effects at levels above
2.0 mmol/L could be very serous and life-threatening. It is
advisable to stop lithium immediately when signs of
toxicity are noticed, without waiting for serum lithium
level confirmation. Most psychiatrists would aim for a
level between 0.6 to 0.8 mmol/L.3 Serum lithium levels are
commonly checked before the morning lithium dose and
around 12 hours after the last or late evening lithium dose.
A recent survey in the United States indicated that the
proportion of patients on lithium not being monitored was
low,4 in contrast to digoxin, theophylline, and other drugs
with similar NTRs.
Serum lithium levels cannot be reliably predicted
from the dosage. While tissue level monitoring helps the
prescribing physician adjust the dosage to avoid acute
toxicity, clinicians prescribing lithium should be aware that
toxicity may occur even when the level is within the thera-
peutic range. Lithium is toxic to many organs, particularly
after long-term use. Metabolic adverse effects are
particularly dangerous and include hypothyroidism, hyper-
parathyroidism and calcium level changes, weight gain
and nephrogenic diabetes insipidus. Hypothyroidism is a
well-known side-effect of lithium, particularly in older
females with a history of hypothyroidism. Goitre occurs in
some patients on lithium and if treatment was to continue
during pregnancy, the neonate should be checked for goitre
and hypothyroidism as well. In addition, patients may
report other adverse effects related to the cardiovascular
system (syncope, electrocardiographic abnormalities,
circulatory failure), nervous system (blurred vision, tremors,
vertigo, ataxia, nystagmus), kidneys (renal impairment), and
gastro-intestinal disturbance (nausea, vomiting, diarrhoea).
Lithium drug-drug interactions, particularly in polyphar-
macy situations, are common in the elderly. Concomitant
non-steroidal anti-inflammatory drugs, diuretics, renin-
angiotensin inhibitors, theophylline, and antibiotics have all
been reported to cause elevations in lithium level and all of
them are commonly prescribed together in geriatric patients.
Ng et al5 in this issue report on their experience in using
lithium to treat thyrotoxicosis. In this sense, an adverse
effect is exploited for good use. Similarly, lithium-induced
leukocytosis has been medically exploited in the manage-
ment of certain leukopenic conditions. Clinicians using
lithium should be aware of all these effects and be prepared
to manage them. They should also appreciate that they are
more likely to occur in the paediatric and geriatric
populations. With all these possible adverse effects and
interactions in mind, a full medical history and laboratory
investigations should be undertaken before the initiation of
lithium therapy. Investigations should include renal and liver
function, thyroid function, electrocardiogram, blood counts,
and biochemistry. Renal function tests should be repeated
every 2 to 3 months and thyroid function tests once or twice
during the first 6 months and then semi-annually or annu-
ally in stable patients, or whenever indicated.3 With careful
clinical monitoring for all these potentially dangerous
adverse affects, plus periodic laboratory examination for
serum lithium level as well as renal, liver, and thyroid func-
tion, many patients will stand to benefit from lithium therapy.
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